benzhydryl-(4,5-dihydro-1H-imidazol-2-yl)-amine | 61611-90-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzhydryl-(4,5-dihydro-1H-imidazol-2-yl)-amine
• 英文别名: 2-benzhydrylimino-imidazolidine；2-Benzhydrylimino-imidazolidin；2-Benzhydryliminoimidazolidine；N-benzhydryl-4,5-dihydro-1H-imidazol-2-amine
• CAS: 61611-90-3
• 化学式: C₁₆H₁₇N₃
• 分子量: 251.331
• InChiKey: UZQOTGNKCVYIFU-UHFFFAOYSA-N

物化性质

• 沸点：
  407.4±55.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  36.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  benzhydryl-(4,5-dihydro-1H-imidazol-2-yl)-amine 生成 2-benzhydrylamino-4,5-dihydro-imidazole-1-carbothioic acid amide
  参考文献：
  名称：

  KOSASAYAMA AKIRA; WATANABE YOSHIFUMI; HIGASHI KUNIO; ISHIKAWA FUMIJOSHI, CHEM. AND PHARM. BULL., 1979, 27, NO 4, 831-840

  摘要：

  DOI：
• 作为产物：
  描述：

  N-benzhydryl-4,5-dihydro-1H-imidazol-2-amine;hydroiodide 以96%的产率得到
  参考文献：
  名称：

  KOSASAYAMA AKIRA; WATANABE YOSHIFUMI; HIGASHI KUNIO; ISHIKAWA FUMIJOSHI, CHEM. AND PHARM. BULL., 1979, 27, NO 4, 831-840

  摘要：

  DOI：

文献信息

• Treatment of diabetes with 2-substituted-1,3-diazacyclic compounds
  申请人：Daiichi Seiyaku Co., Ltd.

  公开号：US04136188A1

  公开（公告）日：1979-01-23

  2-SUBSTITUTED-1,3-DIAZACYCLIC COMPOUNDS OF THE FORMULA: ##STR1## wherein R.sub.1 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; R.sub.2 represents a hydrogen atom, a lower alkoxycarbonyl group, an aliphatic acyl group or an aromatic acyl group, the aromatic ring of which may have one or more substituents selected from a halogen atom, a lower alkyl group, a lower alkoxy group, an acyl group and an acyloxy group; R.sub.3 represents a hydrogen atom, a lower alkyl group, a lower hydroxyalkyl group or an aralkyl group; R.sub.4 represents a hydrogen atom, a lower alkyl group or an aryl group; R.sub.6 represents a cyclohexyl group, a pyridyl group or a phenyl group which may have a substituent selected from a halogen atom, a lower alkyl group and a lower alkoxy group; A represents -N.dbd., an -N(lower alkyl)- group or a methylene group; n represents an integer of from 2 to 4, and a dotted line indicates that a double bond is optional; salts of such derivatives; and the method for preparing such compounds and their salts; the compounds and their salts having a distinct anti-diabetic activity in humans and animals.

  2-取代-1,3-二氮杂环化合物的化学式如下：##STR1## 其中R.sub.1代表氢原子、卤原子、低碳基或低氧基基团；R.sub.2代表氢原子、低碳氧羰基团、脂肪族酰基团或芳香族酰基团，芳香环可能具有一个或多个取代基，选自卤原子、低碳基、低氧基、酰基和酰氧基；R.sub.3代表氢原子、低碳基、低羟基碳基或芳基碳基；R.sub.4代表氢原子、低碳基或芳基；R.sub.6代表环己基、吡啶基或苯基，可能具有一个取代基，选自卤原子、低碳基和低氧基；A代表-N.dbd.、-N(低碳基)-基团或亚甲基基团；n表示2到4之间的整数，虚线表示双键是可选的；这些衍生物的盐；以及制备这种化合物及其盐的方法；这些化合物及其盐在人类和动物中具有明显的抗糖尿病活性。
• Calcium antagonists
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0389765A1

  公开（公告）日：1990-10-03

  The present invention is directed to a new class of cyclic guanidines of the formula: in which Q is represented by a substituent selected from the group consisting of (CH₂)n in which n is an integer from 2-­10, A is a substituent selected from the group consisting of -NH-(CH₂)m in which m is an integer from 0-5, a piperidino substituent, or a piperazino substituent; both Ar and Ar₁ are each independently represented by a phenyl ring, each of which may be optionally substituted with up to 3 substituents, each selected from the group consisting of halogen, alkyl, alkoxy, hydroxy, and trifluoromethyl; and R is represented by either hydrogen or an alkyl; R₁ is represented by hydrogen or an alkyl; the tautomers, and optical isomers thereof; and the pharma­ceutically acceptable acid addition salts thereof; with the provisos that: 1) when Q is represented by (CH₂)2,3,or ₄ , then A is not represented by NH-(CH₂)o; and 2) when Q is represented by (CH₂)₂ and R is an alkyl; then A is not NH-(CH₂), and to their use as calcium antagonists.

  本发明涉及一类新的环鸟苷，其式如下 其中 Q 代表选自 (CH₂)n 组的取代基，其中 n 为 2-10 的整数、 A 是选自由 -NH-(CH₂)m （其中 m 为 0-5 的整数）、哌啶取代基或哌嗪取代基组成的取代基；Ar 和 Ar₁ 均各自独立地由苯基环代表，每个苯基环可任选被最多 3 个取代基取代，每个取代基均选自由卤素、烷基、烷氧基、羟基和三氟甲基组成的组；R₁由氢或烷基表示；R₁由氢或烷基表示；其同素异形体和光学异构体；以及其药学上可接受的酸加成盐；但有以下条件：1) 当 Q 由 (CH₂)2、3 或 ₄ 表示时，则 A 不是 NH-(CH₂)o；以及 2) 当 Q 由 (CH₂)₂ 表示且 R 是烷基时，则 A 不是 NH-(CH₂)，并将它们用作钙拮抗剂。
• JPS5283559A
  申请人：——

  公开号：JPS5283559A

  公开（公告）日：1977-07-12
• US4136188A
  申请人：——

  公开号：US4136188A

  公开（公告）日：1979-01-23
• US4174401A
  申请人：——

  公开号：US4174401A

  公开（公告）日：1979-11-13